Numinus Wellness Inc
TSX:NUMI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (12.8), the stock would be worth CA$-0.09 (272% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.5 | CA$0.05 |
0%
|
| Industry Average | 12.8 | CA$-0.09 |
-272%
|
| Country Average | 18.6 | CA$-0.12 |
-350%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CA |
|
Numinus Wellness Inc
TSX:NUMI
|
106.6m CAD | -7.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.2 |
| Median | 18.6 |
| 70th Percentile | 29.3 |
| Max | 19 628.5 |
Other Multiples
Numinus Wellness Inc
Glance View
Numinus Wellness, Inc. is a health care company that operates a testing and research facility that can support the emerging market of psychedelic therapies to supplement existing options in addressing mental illness, addictions, and post-traumatic stress disorder. The company is headquartered in Vancouver, British Columbia. The Company, through its subsidiary Salvation Botanicals Ltd, has a Health Canada cannabis testing license and dealer’s license. The testing license allows the Company to test and analyze cannabis products from licensed producers, and the dealer’s license allows the Company to test, possess, buy and sell methylenedioxymethamphetamine (MDMA), psilocybin, psilocin, dimethyltryptamine (DMT) and mescaline. Numinus also operates a stand-alone center offering patients integrative health solutions.
